Skip to content

Checked

Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease

NCT06607458 on ClinicalTrials.gov

Study listings come from ClinicalTrials.gov, where sponsors register and update their own studies. A listing does not mean a study is safe or effective, and DatenUS does not recommend any study. Talk with your doctor before joining a clinical trial, and use ClinicalTrials.gov for contact details and full eligibility rules.

Status
Recruiting
Phase
Phase 2
Interventional
Planned enrollment
90
Participants, all sites
U.S. sites
9
In 7 states

Study details

Conditions
Refractory Metastatic Colorectal Cancer
Sponsor
Delcath Systems Inc. (Industry)
Ages
18 years and older
Sex
All
Healthy volunteers
Not accepted
Start
08/05/2025
Primary completion (expected)
December 2026
Last updated by sponsor
10/20/2026

Full eligibility rules, contacts and site names: NCT06607458 on ClinicalTrials.gov

Where the study has sites

Cities with at least one listed U.S. site. Some sites may not be enrolling yet.

  • California: Duarte, Santa Monica
  • Florida: Miami, Tampa
  • Illinois: Chicago
  • Kansas: Overland Park
  • Louisiana: New Orleans
  • North Carolina: Chapel Hill
  • Utah: Salt Lake City

More studies on the same topic

Frequently asked questions

What does recruiting mean?
Recruiting means the study is currently enrolling participants. Not yet recruiting means it has been registered but has not started enrolling. Enrolling by invitation means participants are selected by the study team rather than through open enrollment.
How do I join a clinical trial?
Read the full eligibility criteria and contact information on ClinicalTrials.gov, then talk with your doctor about whether a study may be right for you. The study team decides who can enroll.

Source: ClinicalTrials.gov, National Library of Medicine · Last updated 10/20/2026